Compare Anheuser-Busch Inbev SA (BUD) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Crispr Therapeutics AG — how do they compare? Anheuser-Busch Inbev SA trades at $79.57 (market cap $159.01B), while Crispr Therapeutics AG trades at $53.96 (market cap $5.23B). The key difference: Anheuser-Busch Inbev SA is far larger — about 30.4× Crispr Therapeutics AG's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| BUD | CRSP | |
|---|---|---|
Market Cap | $159.01B | $5.23B |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $76.78 |
52-Week Low | $57.93 | $44.34 |
Enterprise Value | $223.42B | $3.65B |
Dividend Yield | 1.67% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
